BCA
PTCT icon

Berman Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Berman Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$29K Buy
795
+317
+66% +$13K ﹤0.01% 868
2021
Q2 		$20K Buy
478
+285
+148% +$12.2K ﹤0.01% 914
2021
Q1 		$9K Hold
193
– – ﹤0.01% 1071
2020
Q4 		$11K Hold
193
– – ﹤0.01% 894
2020
Q3 		$9K Buy
193
+169
+704% +$8.32K ﹤0.01% 848
2020
Q2 		$1K Buy
+24
New +$1.18K ﹤0.01% 1484

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Berman Capital Advisors's PTCT Position: Q3 2021 in Review

Berman Capital Advisors increased its PTC Therapeutics (PTCT) stake by 66% in Q3 2021, buying an estimated $13K and bringing the position to 795 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #868.

Berman Capital Advisors first reported a position in PTCT in Q2 2020 and has held it in 6 quarters since. 183 funds tracked by Wall St. Rank hold PTCT as of Q3 2021.

  • Berman Capital Advisors held 795 shares of PTC Therapeutics worth $29K as of Q3 2021.
  • Berman Capital Advisors bought 317 PTC Therapeutics shares in Q3 2021, an estimated $13K.
  • PTC Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #868 holding.
  • Berman Capital Advisors first reported a position in PTC Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • 183 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.